← Evidence map

ArticleFrontiers in oncology2025

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.

Yu-Cheng He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis. | Socratic